zur Navigation zum Inhalt
Onkologie 30. März 2009

Sorafenib for recurrent haemangiopericytoma

We report on a patient with relapsed haemangioblastoma with multiple lesions disseminated intracranially and in the spinal cord. The patient, a 33-year-old male presented after repeated surgical resections and after exhaustion of radiation therapy to our outpatient department in March 2008. With immunohistochemistry, we demonstrated widespread expression of VEGFR-2 on the cell mebranes of the tumour cells. Therefore, we started systemic therapy with Sorafenib (NexavarR) with the intention to target VEGFR-2 with dose escalation up to 800 mg/ day. Sorafenib was generally well tolerated. There were no haematological side effects, but the patient developed hand–foot syndrome grade 2 after five months. This necessitated topical therapy, low dose of systemic steroids and a drug holiday from Sorafenib. Sorafenib could be reintroduced after a month and the medication is still ongoing. The Control MRI after 15 months of Sorafenib showed persisting disease stabilization.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben